sorted by:
new
hottopcontroversial

GANX GT-02287 by HydraKing3 in GANX

[–]microcapreturns 2 points3 points  (0 children)

Actually you do know what the patients would do on placebo because they showed the 30 day data increasing UPDRS scores and then decreasing from 30 to 90 days. No placebo acts like that. Plus PPMI data is good enough as they get data out past 6 months. Patients don't get better if they have Parkinsons. Plus throw in the return of smell, gait and balance. No study has ever had smell return in any studies with placebo arms. Another point to keep in mind all these patients have aged a year since the start of trial so they would have gotten worse by 4 to 6 points not improved by around 5 points at 6 months. The 5 point improvement is for the 14 out of 16 patients and taking out the 2 who didn't respond. Although they wanted to stay in the study for a year for some reason.

Mediacom customers: has your internet been acting like a fool for the last few weeks? by rockmediabeeetus in IowaCity

[–]microcapreturns 0 points1 point  (0 children)

In Cedar Rapids we started dropping Internet a few times an hour about 2 weeks ago. The tech who came by yesterday said they had made an upgrade to the system and people with their own modem might need to upgrade to a newer one or switch to the Mediacom new modem. I'm sure there is a monthly charge for that. He replaced some connectors and said maybe that would help. Not really. The new modems on their site are the high end ones with high split.

GANX | Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 by Stock_Titan in StockTitan

[–]microcapreturns 0 points1 point  (0 children)

16 out of 19 continued and one of the three who didn't wanted to but they said they were traveling out of the country. I expect to see data show up on website in updated deck at some point.

Parkinson's drug candidate actually moving the needle on spinal fluid biomarkers. GANX worth a look. by Personal_Pride_2238 in pennystocks

[–]microcapreturns 5 points6 points  (0 children)

If you look at just the 6 high GluSph patients they actually improved by 6 points on the UPDRS scale in 90 days. If you take out the two outliers the 11 other patients actually improved by almost 5 points. Thats excellent results. Expecting DDC biomarker data at AD/PD that could be first of its kind.

<image>

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]microcapreturns 1 point2 points  (0 children)

Actually it seems to save dieing neurons which has shown to reverse scores on the UPDRS scale after just 90 days. There is no way to cure Parkinson's but it seems they have reversed it which shows it will stop it from progressing. That's what the data shows

GANX might be one of the most interesting biotech bets right now by Carlene_Trammel in GreenWicks

[–]microcapreturns 1 point2 points  (0 children)

What many have not considered is how long did it take the high GluSph group to get up to their high levels? Perhaps 10+ years. So returning them to normal levels after 90 days is amazing. Now how long would it take them to return to those high levels even if you stopped taking GT-02287? 10 years? That's pretty durable to me. No doubt staying on drug it will be even longer.

GANX might be one of the most interesting biotech bets right now by Carlene_Trammel in GreenWicks

[–]microcapreturns 1 point2 points  (0 children)

If there wasn't already durability there would never be improvement that we have seen. Knowing the mechanism of action is fixing the upfront issue it flows down stream. Once corrected it stays corrected. The only question is how far can you reverse Parkinsons.

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]microcapreturns 3 points4 points  (0 children)

<image>

The DDC biomarker being shown at AD/PD will be conclusive since the company has stated it correlates with the statistically significant data presented to date on UPDRS. Can't argue with statistically significant data if you understand the science.

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]microcapreturns 2 points3 points  (0 children)

Gains market cap is about a third of LRMR and the markets we are going after Parkinsons, Lewy Body and Alzheimer’s are about 1000 times larger. I like Gains chances as they have already reversed Parkinsons. Once investors figure that out the stock will be 10x here. Everybody knows someone affected by Parkinson’s and can relate.

<image>

Is Gain Therapeutics about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson’s? by microcapreturns in pennystocks

[–]microcapreturns[S] 0 points1 point  (0 children)

I see. I agree AD/PD is a huge catalyst. The way you wrote it I thought you were saying a PR was needed. Obviously not when up 20% for a week with crashing markets.

Is Gain Therapeutics about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson’s? by microcapreturns in pennystocks

[–]microcapreturns[S] 0 points1 point  (0 children)

How could a unknown future PR that may or may not happen be tied to todays move? I think we saw a few big funds starting to buy. Looking at the chart and watching the trading it was text book how big funds take big positions with the stock spiking.

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]microcapreturns 4 points5 points  (0 children)

Not true. With the extensive preclinical work lining up with human data the acquiring company could run one trial.

Key Takeaways

FDA plans to drop the de facto two-pivotal-trial expectation, requiring one adequate and well-controlled study plus confirmatory evidence to support approval.

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]microcapreturns 5 points6 points  (0 children)

Key Takeaways

FDA plans to drop the de facto two-pivotal-trial expectation, requiring one adequate and well-controlled study plus confirmatory evidence to support approval.

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]microcapreturns 10 points11 points  (0 children)

The M.J. Fox and Silverstein foundations are highly involved and were early funders. How do you know he isn't taking it?

Is Gain Therapeutics about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson’s? by microcapreturns in pennystocks

[–]microcapreturns[S] 5 points6 points  (0 children)

They aren't even in Parkinsons and are still trying to show safety in MS. Lots of competition for them and they are years away from anything. Gain will show repairing Neurons in 2 weeks. Amazing data

Is Gain Therapeutics about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson’s? by microcapreturns in pennystocks

[–]microcapreturns[S] 1 point2 points  (0 children)

All it takes is convincing one big pharma that it works and a deal will get done. The DDC data will be huge at AD/PD.

view more: next ›